Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 16 2023 - 10:14AM
Edgar (US Regulatory)
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 6-K
________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2023
Commission File Number: 001-38281
________________________
ERYTECH Pharma S.A.
(Translation of registrant’s name into English)
________________________
60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F S Form 40-F £
INCORPORATION BY REFERENCE
This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-248953 and 333-259690) and registration statements on Form S-8 (File Nos. 333-222673, 333-232670, 333-239429, 333-255900 and 333-265927), of ERYTECH Pharma S.A. (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
Press release
On May 15, 2023, ERYTECH Pharma S.A. issued a press release to provide an update on the announced combination with PHERECYDES.
The full text of the press release is attached as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.
EXHIBIT INDEX
| | | | | | | | |
Exhibit | | Description |
| |
99.1 | | Press Release dated May 15, 2023. |
| |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | | | | | | | | | | | | | | |
| | | | | | |
| | | | ERYTECH Pharma S.A. |
| | | |
Date: | May 16, 2023 | | | By: | | /s/ Eric Soyer |
| | | | | | Name Eric Soyer |
| | | | | | Title: Chief Financial Officer and Chief Operating Officer |
Erytech Pharma (NASDAQ:ERYP)
Historical Stock Chart
From Oct 2024 to Nov 2024
Erytech Pharma (NASDAQ:ERYP)
Historical Stock Chart
From Nov 2023 to Nov 2024